Gyre Therapeutics (GYRE) Long-Term Investments (2010 - 2025)
Gyre Therapeutics (GYRE) reported Long-Term Investments of $107.1 million for Q4 2025, up 66.46% year-over-year from $64.3 million in Q4 2024, and up 66.46% on a QoQ basis from $64.3 million in Q4 2024.
Gyre Therapeutics (GYRE) has 11 years of Long-Term Investments data on file, last reported at $107.1 million in Q4 2025.
- Quarterly Long-Term Investments rose 66.46% year-over-year to $107.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $107.1 million (up 66.46% YoY) and the FY2025 annual result came in at $107.1 million, up 66.46% from the prior year.
- Long-Term Investments grew to $107.1 million in Q4 2025 per GYRE's latest filing, from $64.3 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $107.1 million in Q4 2025 and bottomed at $4.7 million in Q4 2023.
- The 4-year median for Long-Term Investments is $52.5 million (2022), against an average of $54.2 million.
- The widest annual swing landed in 2023, when Long-Term Investments sank 88.38%; it then surged 1261.99% in 2024.
- Tracing GYRE's Long-Term Investments over 4 years: stood at $40.6 million in 2022, then slumped by 88.38% to $4.7 million in 2023, then surged by 1261.99% to $64.3 million in 2024, then soared by 66.46% to $107.1 million in 2025.
- Per Business Quant, the three latest GYRE Long-Term Investments figures stand at $107.1 million (Q4 2025), $64.3 million (Q4 2024), and $4.7 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 107.05 Mn |
| Dec 31, 2024 | 64.31 Mn |
| Dec 31, 2023 | 4.72 Mn |
| Dec 31, 2022 | 40.63 Mn |
| Dec 31, 2020 | 2.54 Mn |
| Sep 30, 2020 | 1.17 Mn |
| Sep 30, 2015 | 825,000.00 |
| Jun 30, 2015 | 828,000.00 |
| Mar 31, 2015 | 1.52 Mn |
| Dec 31, 2014 | 3.42 Mn |
| Sep 30, 2014 | 16.63 Mn |
| Jun 30, 2014 | 25.12 Mn |
| Mar 31, 2014 | 34.90 Mn |
| Dec 31, 2013 | 51.45 Mn |
| Sep 30, 2013 | 58.36 Mn |
| Jun 30, 2013 | 63.81 Mn |
| Mar 31, 2013 | 65.22 Mn |
| Dec 31, 2012 | 59.97 Mn |
| Sep 30, 2012 | 51.91 Mn |
| Jun 30, 2012 | 49.41 Mn |
| Mar 31, 2012 | 47.18 Mn |
| Dec 31, 2011 | 54.27 Mn |
| Sep 30, 2011 | 57.38 Mn |
| Jun 30, 2011 | 57.00 Mn |
| Dec 31, 2010 | 38.49 Mn |